NASDAQ
Talphera, Inc. (TLPH)
♥ 419 Thanks from members
Talphera, Inc. exhibits a speculative profile characterized by advancing clinical trials for its nafamostat NEPHRO CRRT study and conditional financing tranches, balanced against auditor going-concern warnings, substantial shareholder dilution, and micro-cap volatility.